Genetics of personalized medicine: cancer and rare diseases

  • Inês Teles Siefers Alves
  • Manuel Condinho
  • Sónia Custódio
  • Bruna F. Pereira
  • Rafael Fernandes
  • Vânia Gonçalves
  • Paulo J. da Costa
  • Rafaela Lacerda
  • Ana Rita Marques
  • Patrícia Martins-Dias
  • Gonçalo R. Nogueira
  • Ana Rita Neves
  • Patrícia Pinho
  • Raquel Rodrigues
  • Eva Rolo
  • Joana Silva
  • André Travessa
  • Rosário Pinto Leite
  • Ana Sousa
  • Luísa Romão
Commentary

Abstract

The 21st annual meeting of the Portuguese Society of Human Genetics (SPGH), organized by Luísa Romão, Ana Sousa and Rosário Pinto Leite, was held in Caparica, Portugal, from the 16th to the 18th of November 2017. Having entered an era in which personalized medicine is emerging as a paradigm for disease diagnosis, treatment and prevention, the program of this meeting intended to include lectures by leading national and international scientists presenting exceptional findings on the genetics of personalized medicine. Various topics were discussed, including cancer genetics, transcriptome dynamics and novel therapeutics for cancers and rare disorders that are designed to specifically target molecular alterations in individual patients. Several panel discussions were held to emphasize (ethical) issues associated with personalized medicine, including genetic cancer counseling.

Keywords

Human genetics Personalized medicine Cancer genetics Genome architecture Rare disorders 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    E.T. Wang, R. Sandberg, S. Luo, I. Khrebtukova, L. Zhang, C. Mayr, S.F. Kingsmore, G.P. Schroth, C.B. Burge, Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470–476 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Q. Pan, O. Shai, L.J. Lee, B.J. Frey, B.J. Blencowe, Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413–1415 (2008)CrossRefPubMedGoogle Scholar
  3. 3.
    T. Maniatis, B. Tasic, Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 418, 236–243 (2002)CrossRefPubMedGoogle Scholar
  4. 4.
    D.L. Bentley, Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors. Curr. Opin. Cell Biol. 17, 251–256 (2005)CrossRefPubMedGoogle Scholar
  5. 5.
    J.P. Staley, C. Guthrie, Mechanical devices of the spliceosome: motors, clocks, springs, and things. Cell 92, 315–326 (1998)CrossRefPubMedGoogle Scholar
  6. 6.
    Z. Zhou, L.J. Licklider, S.P. Gygi, R. Reed, Comprehensive proteomic analysis of the human spliceosome. Nature 419, 182–185 (2002)CrossRefPubMedGoogle Scholar
  7. 7.
    P.J. da Costa, J. Menezes, L. Romão, The role of alternative splicing coupled to nonsense-mediated mRNA decay in human disease. Int. J. Biochem. Cell Biol. 91, 168–175 (2017).  https://doi.org/10.1016/j.biocel.2017.07.013 CrossRefPubMedGoogle Scholar
  8. 8.
    C.J. David, J.L. Manley, Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24, 2343–2364 (2010)CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    B. Sumithra, U. Saxena, A.B. Das, Alternative splicing within the Wnt signaling pathway: role in cancer development. Cell. Oncol. 39, 1–13 (2016)CrossRefGoogle Scholar
  10. 10.
    M. Imielinski, A.H. Berger, P.S. Hammerman, B. Hernandez, T.J. Pugh, E. Hodis, J. Cho, J. Suh, M. Capelletti, A. Sivachenko, C. Sougnez, D. Auclair, M.S. Lawrence, P. Stojanov, K. Cibulskis, K. Choi, L. de Waal, T. Sharifnia, A. Brooks, H. Greulich, S. Banerji, T. Zander, D. Seidel, F. Leenders, S. Ansén, C. Ludwig, W. Engel-Riedel, E. Stoelben, J. Wolf, C. Goparju, K. Thompson, W. Winckler, D. Kwiatkowski, B.E. Johnson, P.A. Jänne, V.A. Miller, W. Pao, W.D. Travis, H.I. Pass, S.B. Gabriel, E.S. Lander, R.K. Thomas, L.A. Garraway, G. Getz, M. Meyerson, Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107–1120 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    J. Hernández, E. Bechara, D. Schlesinger, J. Delgado, L. Serrano, J. Valcárcel, Tumor suppressor properties of the splicing regulatory factor RBM10. RNA Biol. 13, 466–472 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    E.G. Bechara, E. Sebestyén, I. Bernardis, E. Eyras, J. Valcárcel, RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol. Cell 52, 720–733 (2013)CrossRefPubMedGoogle Scholar
  13. 13.
    L. Wurth, P. Papasaikas, D. Olmeda, N. Bley, G.T. Calvo, S. Guerrero, D. Cerezo-Wallis, J. Martinez-Useros, M. García-Fernández, S. Hüttelmaier, M.S. Soengas, F. Gebauer, UNR/CSDE1 drives a post-transcriptional program to promote melanoma invasion and metastasis. Cancer Cell 30, 694–707 (2016)CrossRefPubMedGoogle Scholar
  14. 14.
    A.R. Morris, N. Mukherjee, J.D. Keene, Systematic analysis of posttranscriptional gene expression. Wiley Interdiscip. Rev. Syst. Biol. Med. 2, 162–180 (2010)CrossRefPubMedGoogle Scholar
  15. 15.
    L. Wurth, F. Gebauer, RNA-binding proteins, multifaceted translational regulators in cancer. Biochim. Biophys. Acta-Gene Regul. Mech. 1849, 881–886 (2015)CrossRefGoogle Scholar
  16. 16.
    P. Papasaikas, J.R. Tejedor, L. Vigevani, J. Valcárcel, Functional splicing network reveals extensive regulatory potential of the core spliceosomal machinery. Mol. Cell 57, 7–22 (2015)CrossRefPubMedGoogle Scholar
  17. 17.
    A.K. Goroncy, S. Koshiba, N. Tochio, T. Tomizawa, M. Inoue, S. Watanabe, T. Harada, A. Tanaka, O. Ohara, T. Kigawa, S. Yokoyama, The NMR solution structures of the five constituent cold-shock domains (CSD) of the human UNR (upstream of N-ras) protein. J. Struct. Funct. Genom. 11, 181–188 (2010)CrossRefGoogle Scholar
  18. 18.
    G. Triqueneaux, M. Velten, P. Franzon, F. Dautry, H. Jacquemin-Sablon, RNA binding specificity of Unr, a protein with five cold shock domains. Nucleic Acids Res. 27, 1926–1934 (1999)CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    D. Huang, H. Pospiech, T. Kesti, J.E. Syva, Structural organization and splice variants of the POLE1 gene encoding the catalytic subunit of human DNA polymerase ε. Biochem. J. 339, 657–665 (1999)CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    C. Palles, J.B. Cazier, K.M. Howarth, E. Domingo, A.M. Jones, P. Broderick, Z. Kemp, S.L. Spain, E.G. Almeida, I. Salguero, A. Sherborne, D. Chubb, L.G. Carvajal-Carmona, Y. Ma, K. Kaur, S. Dobbins, E. Barclay, M. Gorman, L. Martin, M.B. Kovac, S. Humphray, A. Lucassen, C.C. Holmes, D. Bentley, P. Donnelly, J. Taylor, C. Petridis, R. Roylance, E.J. Sawyer, D.J. Kerr, S. Clark, J. Grimes, S.E. Kearsey, H.J.W. Thomas, G. McVean, R.S. Houlston, I. Tomlinson, Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136–144 (2013)CrossRefPubMedGoogle Scholar
  21. 21.
    M.M. Hahn, R.M. de Voer, N. Hoogerbrugge, M.J.L. Ligtenberg, R.P. Kuiper, A. Geurts van Kessel, The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. Cell. Oncol. 39, 491–510 (2016)CrossRefGoogle Scholar
  22. 22.
    D. Chubb, P. Broderick, S.E. Dobbins, M. Frampton, B. Kinnersley, S. Penegar, A. Price, Y.P. Ma, A.L. Sherborne, C. Palles, M.N. Timofeeva, D.T. Bishop, M.G. Dunlop, I. Tomlinson, R.S. Houlston, Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat. Commun. 7, 11883 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    K. El Bairi, A.H. Kandhro, A. Gouri, W. Mahfoud, N. Louanjli, B. Saadani, S. Afqir, M. Amrani, Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. Cell. Oncol. 40, 105–118 (2017)CrossRefGoogle Scholar
  24. 24.
    A. Chavez-Gonzalez, B. Bakhshinejad, K. Pakravan, M.L. Guzman, S. Babashah, Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. Cell. Oncol. 40, 1–20 (2017)CrossRefGoogle Scholar
  25. 25.
    M. Yousefi, T. Bahrami, A. Salmaninejad, R. Nosrati, P. Ghaffari, S.H. Ghaffari, Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. Cell. Oncol. 40, 419–441 (2017)CrossRefGoogle Scholar
  26. 26.
    P.O. Pietarinen, C.A. Eide, P. Ayuda-Durán, S. Potdar, H. Kuusanmäki, E.I. Andersson, J.P. Mpindi, T. Pemovska, M. Kontro, C.A. Heckman, O. Kallioniemi, K. Wennerberg, H. Hjorth-Hansen, B.J. Druker, J.M. Enserink, J.W. Tyner, S. Mustjoki, K. Porkka, Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget 8, 22606–22615 (2017)CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    J. Tang, L. Karhinen, T. Xu, A. Szwajda, B. Yadav, K. Wennerberg, T. Aittokallio, Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways. PLoS Comput. Biol. 9, e1003226 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    B. Yadav, T. Pemovska, A. Szwajda, E. Kulesskiy, M. Kontro, R. Karjalainen, M.M. Majumder, D. Malani, A. Murumägi, J. Knowles, K. Porkka, C. Heckman, O. Kallioniemi, K. Wennerberg, T. Aittokallio, Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, 5193 (2015)CrossRefGoogle Scholar
  29. 29.
    H. Kuusanmäki, O. Dufva, E. Parri, A.J. van Adrichem, H. Rajala, M.M. Majumder, B. Yadav, A. Parsons, W.C. Chan, K. Wennerberg, S. Mustjoki, C.A. Heckman, Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget 8, 97516–97527 (2017)CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    R. Demsky, J. McCuaig, M. Maganti, K.J. Murphy, B. Rosen, S.R. Armel, Keeping it simple: Genetics referrals for all invasive serous ovarian cancers. Gynecol. Oncol. 130, 329–333 (2013)CrossRefPubMedGoogle Scholar
  31. 31.
    A. Lanceley, Z. Eagle, G. Ogden, S. Gessler, K. Razvi, J.A. Ledermann, L. Side, Family history and women with ovarian cancer. Int. J. Gynecol. Cancer 22, 254–259 (2012)CrossRefPubMedGoogle Scholar
  32. 32.
    A. George, D. Riddell, S. Seal, S. Talukdar, S. Mahamdallie, E. Ruark, V. Cloke, I. Slade, Z. Kemp, M. Gore, A. Strydom, S. Banerjee, H. Hanson, N. Rahman, Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci. Rep. 6, 29506 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Guidance and guidelines, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE [Internet]. United Kingdom, National Institute for Health and Clinical Excellence. https://www.nice.org.uk/guidance/cg164/chapter/Recommendations Accessed 11 December 2017
  34. 34.
    I. Slade, H. Hanson, A. George, K. Kohut, A. Strydom, S. Wordsworth, N. Rahman, A cost analysis of a cancer genetic service model in the UK. J. Community Genet. 7, 185–194 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Assembly of the Republic, in Diário da República Eletrónico, Legislação, Lei n.o 12/2005- Diário da República n.o 18/2005, Série I-A de 2005–01-26- DRE. 606–611 [Internet]. Portugal, Diário da República Eletrónico. https://dre.pt/web/guest/pesquisa/-/search/624463/details/normal?_search_WAR_drefrontofficeportlet_print_preview=print-preview Accessed 11 December 2017
  36. 36.
    Assembly of the Republic, in Diário da República Eletrónico, Legislação, Decreto-Lei n.o 131/2014 – Ministério da Saúde–Regulamenta a Lei n.o 12/2005, de 26 de janeiro [Internet]. Portugal, Diário da República Eletrónico. http://direitodamedicina.sanchoeassociados.com/arquivo/decreto-lei-n-o-1312014-ministerio-da-saude-regulamenta-a-lei-n-o-122005-de-26-de-janeiro-no-que-se-refere-a-protecao-e-confidencialidade-da-informacao-genetica-as-bases-de-da/ Accessed 11 December 2017Google Scholar
  37. 37.
    Commissioner of the Press Announcements in FDA, U.S. Food and Drug, Press Announcements. FDA approves first cancer treatment for any solid tumor with a specific genetic feature [Internet]. USA, FDA. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htm Accessed 11 December 2017
  38. 38.
    D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, B. Biedrzycki, R.C. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, S.M. Duffy, R.M. Goldberg, A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R.H. Hruban, L.D. Wood, N. Cuka, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, S. Zhou, T.C. Cornish, J.M. Taube, R.A. Anders, J.R. Eshleman, B. Vogelstein, L.A. Diaz, PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    D.T. Le, J.N. Durham, K.N. Smith, H. Wang, B.R. Bartlett, L.K. Aulakh, S. Lu, H. Kemberling, C. Wilt, B.S. Luber, F. Wong, N.S. Azad, A.A. Rucki, D. Laheru, R. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, T.F. Greten, A.G. Duffy, K.K. Ciombor, A.D. Eyring, B.H. Lam, A. Joe, S.P. Kang, M. Holdhoff, L. Danilova, L. Cope, C. Meyer, S. Zhou, R.M. Goldberg, D.K. Armstrong, K.M. Bever, A.N. Fader, J. Taube, F. Housseau, D. Spetzler, N. Xiao, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, J.R. Eshleman, B. Vogelstein, R.A. Anders, L.A. Diaz, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017)CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    M. Robson, S.A. Im, E. Senkus, B. Xu, S.M. Domchek, N. Masuda, S. Delaloge, W. Li, N. Tung, A. Armstrong, W. Wu, C. Goessl, S. Runswick, P. Conte, Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523–533 (2017)CrossRefPubMedGoogle Scholar
  41. 41.
    European public assessment report (EPAR) in European Medicines Agency (EMA), Science Medicines Health, Human Medicine. Lynparza [Internet]. United Kingdom, EMA. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003726/human_med_001831.jsp&mid=WC0b01ac058001d124 Accessed 15 December 2017
  42. 42.
    F.R. Vogenberg, C. Isaacson Barash, M. Pursel, Personalized medicine: part 1: evolution and development into theranostics. P & T 35, 560–576 (2010)Google Scholar
  43. 43.
    Serviço Nacional de Saúde (SNS), Medicina personalizada na Europa [Internet]. Portugal, SNS. https://www.sns.gov.pt/noticias/2017/10/20/medicina-personalizada-na-europa/ Accessed 18 December 2017
  44. 44.
    N.L. Bragazzi, From P0 to P6 medicine, a model of highly participatory, narrative, interactive, and "augmented" medicine: some considerations on Salvatore Iaconesi’s clinical story. Patient Prefer Adherence 7, 353–359 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    E.P. Bottinger, Foundations, promises and uncertainties of personalized medicine. Mt Sinai J. Med. 74, 15–21 (2007)CrossRefPubMedGoogle Scholar
  46. 46.
    M.A. Hamburg, F.S. Collins, The path to personalized medicine. N. Engl. J. Med. 363, 301–304 (2010)CrossRefPubMedGoogle Scholar
  47. 47.
    M.F. Haward, J.M. Lorenz, Communicating risk under conditions of uncertainty: not as simple as it may seem. Acta Paediatr. 100, 651–652 (2011)CrossRefPubMedGoogle Scholar
  48. 48.
    N.J. Schork, Personalized medicine: time for one-person trials. Nature 520, 609–611 (2015)CrossRefPubMedGoogle Scholar

Copyright information

© International Society for Cellular Oncology 2018

Authors and Affiliations

  • Inês Teles Siefers Alves
    • 1
  • Manuel Condinho
    • 2
    • 3
  • Sónia Custódio
    • 4
  • Bruna F. Pereira
    • 2
    • 3
  • Rafael Fernandes
    • 2
    • 3
  • Vânia Gonçalves
    • 2
    • 3
  • Paulo J. da Costa
    • 2
    • 3
  • Rafaela Lacerda
    • 2
    • 3
  • Ana Rita Marques
    • 2
    • 3
  • Patrícia Martins-Dias
    • 2
    • 3
  • Gonçalo R. Nogueira
    • 2
    • 3
  • Ana Rita Neves
    • 2
    • 3
  • Patrícia Pinho
    • 5
  • Raquel Rodrigues
    • 4
  • Eva Rolo
    • 4
  • Joana Silva
    • 2
    • 3
  • André Travessa
    • 4
  • Rosário Pinto Leite
    • 5
  • Ana Sousa
    • 4
  • Luísa Romão
    • 2
    • 3
  1. 1.Department of Cell Biology and BiochemistrySpringer Science + Business Media B.VDordrechtThe Netherlands
  2. 2.Department of Human GeneticsNational Institute of Health Doutor Ricardo JorgeLisbonPortugal
  3. 3.Biosystems & Integrative Sciences Institute (BioISI), Faculty of SciencesUniversity of LisbonLisbonPortugal
  4. 4.Medical Genetics Service, Pediatric DepartmentHospital Santa MariaLisbonPortugal
  5. 5.Genetics LaboratoryHospital Center of Trás-os-Montes and Alto DouroVila RealPortugal

Personalised recommendations